The developer of T-cell receptor therapies backed by Boehringer Ingelheim raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.
T-Knife, a Germany-based developer of T-cell receptor therapeutics backed by pharmaceutical company Boehringer Ingelheim, has raised $110m in a series B round led by investment and financial services group Fidelity Management & Research Company.
The round was filled out by sovereign wealth fund Qatar Investment Authority, Life Science Partners, Casdin Capital, Sixty Degree Capital, CaaS Capital, RA Capital Management, Versant Ventures and Andera Partners.
Founded in 2018 as a spinout of Max Delbrück Center for Molecular Medicine (MDC), T-Knife develops…
